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 1 
ABSTRACT 
Patellin1 (PATL1) is an Arabidopsis thaliana membrane-trafficking protein that 
plays a key role in cell plate formation and expansion in plant roots. Previous vesicle 
cosedimentation assays revealed that PATL1’s Sec14 domain has a remarkably specific 
phospholipid binding profile. Unlike the majority of Sec14 proteins, it exhibits very weak 
affinity for phosphatidylcholine (PC). Instead, it generally favors phosphatidylinositol 
(PI) and some of PI’s phosphorylated derivatives, with a large preference for 
phosphatidylinositol-5-phosphate, PI(5)P. Molecular dynamics (MD) simulations and 
electrostatic analyses have suggested that several charged amino acids are responsible for 
PATL1’s binding specificity. The current work aimed to verify these computationally 
predicted binding interactions by experimentally measuring the lipid binding of PATL1 
using tryptophan fluorescence spectroscopy, isothermal titration calorimetry (ITC), and 
rapid equilibrium dialysis. None of these methods were capable of quantitatively 
evaluating PATL1 binding. This inability was partly attributed to protein co-purification 
with bacterial cell phospholipids and their occupation of PATL1’s Sec14 lipid binding 
domain. Although this co-purification was not definitively proven, several experiments 
support the hypothesis. The addition of a denaturation step to the PATL1 purification 
protocol was proposed. Due to its high specificity, PATL1 is an ideal model for studying 
PI binding interactions. Further study will support research toward designing proteins that 








Phosphoinositides in Cell Signaling 
Phosphatidylinositol (PI) is a membrane lipid characterized by a negatively 
charged inositol headgroup,
1
 which is readily phosphorylated and dephosphorylated by 
varied and highly specific
2
 kinases and phosphatases.
3,4
 Consequently, seven different 
species of phosphorylated PI derivatives, known as phosphoinositides,
5
 are produced 
within the mammalian cell: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P, PI(3,5)P, PI(4,5P), and 
PI(3,4,5)P.
1,6
 These phosphatidylinositol- phosphates (PIP) are not static in the cell but 
are subjected to rapid interconversion by various kinases and phosphatases, some of 
which will be discussed in further detail later. This produces a dynamic PIP equilibrium 
in the cell, as shown in Figure 1. Although present in much smaller concentrations than 
other phospholipids in the cell, the phosphoinositides are increasingly gaining recognition 






 The production and degradation of mono-, bis-, and tris-phosphorylated 
PI derivatives in the cell. Several kinases, including phosphoinositide 3-kinase (PI 3-K) 
and phosphoinositide kinases I, II, and III, among others, phosphorylate the inositol 
headgroup to produce seven phosphoinositide species in mammalian cells. Phosphate 
groups are indicated by blue circles. The complete phosphatidylinositol lipid can be seen 
on the left. 
 
Phosphoinositol lipids serve both as molecular precursors to other signaling 




 from cellular caches and activate a series of serine/threonine 
kinases, respectively),
2
 and as important regulatory molecules in their own right. 
9
 PI(3)P, 
PI(4,5)P and PI(3,4,5)P have long been established as important second messengers,
10
 or 
molecules that relay messages from membrane receptors to the rest of the cell. More 
recently, the somewhat poorly understood PI(5)P lipid has received increased attention as 
a second messenger.
11
 Notably, individual phosphoinositide species localize to certain 
areas in the plasma membrane or in endosomes,
12
 forming special “compartments” that 
draw specific proteins from the cytosol to the membrane interface.
7
 Subsequently, these 
phosphoinositide molecules often regulate the newly recruited proteins, facilitating endo- 
and exocytosis,
12




  and the 
mediation of a number of signaling pathways.
1
 Aberrations in these PI-driven pathways 
have dire consequences.  
Imbalances in PIP metabolism, caused by mutations in PI-metabolizing kinases, 
phosphatases, and phospholipases, contribute to the development of a diverse collection 
of devastating human diseases.
7
 The rare neurological disorders myotubular myopathy, 
lethal congenital contractural syndrome (LCCS), Charcot-Marie-Tooth disease, and Lowe 
syndrome are all commonly cited as diseases of anomalous PI signaling.
9, 15
 Myotubular 
myopathy, which causes muscle weakness so severe that sufferers are unable to breathe 
on their own and often die within the first year of life, and Lowe syndrome, characterized 
by mental retardation, cataracts, and kidney disease, are both X-linked disorders caused 
by mutations in genes that encode inositol phosphatases.
15
 Cells of patients with 
myotubular myopathy have faulty myotubularin proteins, which dephosphorylate PI(3)P 
and PI(3,5)P at their three positions, while those with Lowe syndrome exhibit abnormal 
 4 
levels of PI(4,5)P due to mutations in the inositol 5-phosphatase OCRL. Conversely, 
LCCS, a disease of early onset neuronal degeneration in the spinal cord,
16
 occurs due to 
malfunctioning of PIPKIγ, an inositol 5-kinase responsible for promoting PI(4,5)P 
production in the nervous system.
17
 
One of the most active areas of PI signaling research as it relates to human health 
is the study of how these pathways affect the development, metastasis, and prognosis of 
certain cancers. Researchers are particularly interested in abnormalities of the PI3K 
pathway. PI3K is a heterodimeric protein that is activated by receptor tyrosine kinases 
(RTKs), G protein-coupled receptors (GPCRs), and some oncogenes
18
 and is responsible 
for converting PI(4,5)P to PI(3,4,5)P at the plasma membrane.
19
 Although activating 
mutations in PI3K are most often the cause of cancer when the PI3K pathway goes awry, 
alterations in other proteins in the pathway can also prompt carcinogenesis.
18
  
Deletions or inactivations of phosphate tensin homolog (PTEN), a membrane 
protein tasked with dephosphorylating newly minted PI(3,4,5)P at its three position, are 
frequently implicated in gastric, endometrial, melanoma, and prostate tumorigenesis. The 
excess PI(3,4,5)P produced in cells with upregulated PI3K, downregulated PTEN, or both 
impacts a number of downstream enzymes that promote cell proliferation, growth, 
survival, differentiation, glucose metabolism, and DNA repair, as shown in Figure 2.
18
 
One such enzyme is Akt, a serine-threonine protein kinase that is activated by membrane 
docking to PI(3,4,5)P
18
 and phosphorylates a number of substrates involved in cell 
proliferation and anti-apoptosis.
20
 Notably, tumors containing cells with overactive Akt 




 and are more likely to be resistant 





Figure 2. Sites of Carcinogenic Mutations in the PI3K Pathway. Common mutations 
within the PI3K pathway are marked with pink stars. Activating mutations in PI3K and 
AKT and deletions in PTEN
24
 all contribute to cell growth, survival, and metabolism, 
while stifling certain apoptosis pathways. This leads to the development of several 
cancers. Figure adapted from Jose Baselga, reference 24. 
 
All in the Superfamily: Sec14p and Related SEC14 Proteins 
 The SEC14 domain is an ancient protein module
25
 found in over 1550 proteins 
from organisms across the Eukaryota domain.
 6, 25
 The prototype for the SEC14 domain is 
Sec14p, a globular, two-lobed phosphatidylinositol transfer protein (PITP) that exhibits 
transient membrane association in Saccharomyces cerevisiae yeast cells. 
26
 As a PITP, 
Sec14p binds phosphatidylinositol (PI) and phosphatidylcholine (PC). Traditionally, it 
was widely thought that the protein subsequently transported the phospholipids in 
opposite directions between intracellular membranes in the cell.
6
 More recent research 
maintains that Sec14p and other SEC14 proteins act as lipid sensors and moderate 




 Although the exact mechanism by which Sec14p functions is still 
unknown, it is widely thought to regulate secretory vesicle transport in the yeast trans-
Golgi network and coordinate lipid metabolism to protein activities involved in 
membrane trafficking.
 27 
Several groups have proposed mechanisms for the regulatory 
roles of SEC14 proteins.  
 In early theories, scientists posited that SEC14 proteins regulated lipid 
metabolism by physically transporting phospholipids between the plasma and 
intracellular membranes, moving them from higher to lower concentrations within the 
cell.
28
 Although this early research also proposed a potential role for SEC14 molecules in 
improving the ability of PI kinases to bind PI lipids,
29
 more recent findings have 
emphasized this function over the one in which Sec14p literally transfers lipids from one 
point to another. In this way, scientists have coined the “nanoreactor” model of 
heterotypic exchange, which is defined as an interaction between a lipid bound PITP and 












Figure 3. Two models of PITP function. A) In the older but less popular transfer model, 
the PITP traffics PI and PC back and forth between the endoplasmic reticulum (on the 
left) and intracellular membranes (on the right) that tend to be deficient in PI. B) The 
nanoreactor model represents a more complicated scenario. “Heterotypic exchange,” in 
 7 
which the protein binds PC lipid prior to PI lipid inducing a conformational change in 
Sec14, is thought to occur. This event allows the Sec14p binding pocket to present the PI 





 A recent study examining the SEC14 homolog Sfh1 suggests that Sfh1 and, by 
extension, other SEC14 PITPs, operate by binding a PI molecule followed by a “priming 
ligand at a different site.”30 The priming ligand, usually the neutral phospholipid 
phosphatidylcholine, is an allosteric activator that serves to “prime” the SEC14 protein 
for binding PI in such as way that its inositol ring is exposed to nearby PI kinases.
31
 
These kinases phosphorylate the inositol headgroup to produce an array of 
phosphoinositides within the cell and, thus, mediate its PI metabolism. A related theory 
contends that, rather than binding at distinct locations, the priming ligand and PI 
molecule share a single binding site, and the slow exit of the priming ligand from that site 
effectively keeps the PI molecule exposed to membrane-docked enzymes. It is therefore 
especially susceptible to alteration by kinases. Just as before, the SEC14 protein’s 
function is primarily to contribute to whichever compartment of PI molecules requires 
it.
31
 The nanoreactor theory has been bolstered by a recent molecular dynamics study of 
Sec14p, in which authors found that the protein has a hinged, helical “gate” that rapidly 
opens and closes in a “breathing” pattern over the hydrophobic binding pocket.32 The rate 
of these oscillations agrees with the high rate at which Sec14p facilitates PI/PC exchange, 
suggesting that the SEC14 module is first and foremost an agent of heterotypic exchange 




In addition to the host of diseases caused by imbalances in PI metabolism already 
discussed above, there are several mammalian diseases caused specifically by defects in 
PIP production due to mutant SEC14 domains.  Some of the well-known 
 8 
neurodegenerative disorders associated with such defects, including ataxia with vitamin E 
deficiency and Bothnia dystrophy, can cause blindness. Others, such as aberrations in the 
Trio and Cdc42GAP proteins have been linked to tumorigenesis in bladder cancer and 
human chronic myeloid leukemia, respectively.
25
 The molecular mechanisms driving the 
progression of these and other SEC14-related diseases are not yet known, but researchers 
recently made progress in elucidating them by unveiling the first SEC14 small molecule 
inhibitor. This inhibitor will enable scientists to study SEC14-deficient cells and their 





 Patellin1 (PATL1) is a SEC14 protein with a remarkably specific lipid binding 
profile. Discovered by the Peterman lab at Wellesley in 2004, Patellin1 is a membrane-
trafficking protein in the roots of Arabidopsis thaliana. Recent immunolocalization and 
biochemical fractionation studies suggest that it is recruited from the cytoplasm and 
localizes to the cell plate during cytokinesis, contributing to the plate’s expansion and 
maturation. 
35
 PATL1’s Sec14 lipid binding domain shares high homology with that of 
Sec14p (they have 26%/48% amino acid similarity/identity), 
35
 which is unsurprising 
given their similar membrane-trafficking roles in the cell. Notably, the primary structure 
of the hydrophobic binding pocket within Sec14p is largely conserved in PATL1, 
suggesting that the proteins may share similar patterns and mechanisms of binding. As a 
“non-classical” PITP,25 PATL1 does not bind phosphatidylcholine.35 However, it does 




Namely, PATL1 favors phosphatidylinositol-5-phosphate (PI(5)P), phosphatidylinositol-







Figure 4. The Phosphoinositide Binding Specificity of PATL1. Vesicle 
cosedimentation assays performed by Peterman et al. showed that PATL1 has a 
significant binding preference for vesicles containing 10:1 ratios of PE lipid to PI(5)P, 
PI45P, and PI3P, respectively. No general pattern (i.e. position or number of phosphate 
groups) emerged as a predictor of PATL1’s binding strength to a given phosphoinositide 
molecule. Complete methods can be found in Peterman, et al., 2004. 
 
 In previous computer modeling experiments from the Elmore lab, several of 
PATL1’s charged amino acids were predicted to be particularly important for binding PI 
and phosphorylated derivatives of PI. Simulations of a PATL1 model (based on the 
crystal structure of homolog Sfh1) in the presence of PC, PE, PI35P, PI4P, PI, PI3P, 
 10 
PI45P and PI(5)P lipids were performed, and the energies between the lipid molecules 
and each residue of PATL1 were calculated. For comparison’s sake, three methods were 
used. The molecular dynamics (MD) method used an explicit solvent model and took the 
movement of the system into account, and the second method modeled water 
electrostatically but used only the static homology model of PATL1. The third method, 
MM-PBSA on multiple frames of the equilibrated system, was something of a Goldilocks 
approach, incorporating both conformational changes of the protein and any potential 
interference from individual solvent molecules into the calculations. Each method 
showed that Arg90 was universally important for phospholipid binding, coordinating the 
phosphate moieties of not only the PI lipids, but those of the PC and PE lipids as well. 
Arg175 and Lys179 were beneficial as well, but on a somewhat more limited scope, only 
improving phosphoinositide binding to PATL1.
36
 The preference of PATL1 for PI and 
PI-derived lipids can likely be attributed to the presence of Arg175 and Lys179, whose 
positive charges attract the negatively charged inositol-phosphate moiety.  
 Other residues also contributed to PATL1’s specificity, sometimes in unexpected 
ways. Interactions between PATL1’s negatively charged residue Glu141 and negatively 
charged PI lipids were highly energetically unfavorable, yet PATL1 bound the PI lipids 
very effectively. It was therefore hypothesized that Glu141 has a role in positioning PI 
lipids into a specific configuration using repulsive forces. A similar role could be 
proposed for Asp12, which was found to be in close proximity to PI35P within the 
binding site. Arg11 provided a clear benefit for binding phosphorylated PI lipids, 
although the lipids that interacted especially well with the positively charged residue 
varied depending on the computational method used. Simulations using the standard MD 
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forcefield showed that Arg11’s interactions with PI4P were especially favorable, whereas 
MM-PBSA calculations showed that Arg11 interacted most strongly with PI4P and 
PI35P, the most weakly bound PI lipids. Interestingly, MM-PBSA calculations on initial 
PATL1-lipid homology models indicated that Arg11 was especially drawn to the 
monophosphorylated lipids PI4P and PI3P, but not PI(5)P. The present study seeks to 
verify these computational results using in vitro protein-lipid assays to measure the 




Phosphoinositide Detection Proteins 
 In order to learn about the identity of phosphoinositides in cellular membranes, 
scientists have developed several inositol lipid imaging techniques that rely on detection 
by fluorescent proteins.
12
 Early versions of these techniques required scientists to analyze 
fractions of different cellular organelles by centrifuging the samples and detecting the 
relevant materials once they had successfully been separated. Although this method 
provides researchers with accurate information regarding relative lipid concentrations 
within membranes, it also destroys the their heterogeneity and integrity.
12
 In order to 
more completely investigate the cellular localization and migration of phosphoinositides, 
researchers have recently developed techniques for live cell lipid imaging, which allow 
for a more dynamic and accurate view of lipid distribution within the cell. 
37
 Several 
protein domains with known preferences for certain PIPs, including the Pleckstrin 
homolgy, Phox homology, FYVE, and phosphoinositide-dependent kinase 1 families, 
have been expressed and fused with green fluorescent protein (GFP) tags.
7, 16-18
 
Mammalian cells are transfected with the fused proteins,
2
 which bind PIPs at production 
 12 
sites within the cell. Scientists can then view patterns of localization using confocal 
microscopy
38
 or “watch” them using fluorescence resonance energy transfer spectroscopy 
(FRET).
2
 (Figure 5) 
 
Figure 5. Phosphoinositide detection proteins highlight different PI “compartments” 
in cells. GFP fusion PIDP modules transfected into Chinese hamster ovary cells reveal 
that PI(4,5)P2 (A), PI(4)P (B), and PI(3)P (C) localize to the plasma membrane, Golgi 
apparatus, and to endosomes, respectively. Cell nuclei are shown in blue. Fluorescence 





While researchers are eager to use this technology to learn more about the 
phosphoinositide signaling system and its implications for human diseases, there are 
several aspects of the procedure that need to be optimized.  
 Scientists involved in lipid probe design are primarily concerned with the affinity 
of the lipid probe for the ligand, the effectiveness of the fluorophore, and the ability of 
the cell to function as it normally would when it is forced to contend with an excess of 
PI-binding proteins.
38
 The affinity of the probe for the ligand must be strong, but not so 
strong that it interferes with cellular processes. Balla et al. list the ideal lipid-probe 
affinity as being between Kd = 0.5 – 1 uM. Naturally occurring PIP-binding domains, 
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therefore, are popular choices for lipid probes, as their nomadic existence in the cell is 
driven by transient interactions between membrane lipids.
37
 That being said, some of 
these natural PIP-binding domains simply do not bind well enough to sought-after ligands 
in experimental settings. Further, some do not take well to the fluorescent tag, and the 




 Due to these challenges, it seems wise to start working in earnest toward 
developing designer lipid probes with the ability to detect phosphoinositides in the cell to 
a certain degree of accuracy and under a wide range of conditions. The need for lipid 
probe design is underscored by the present failure of a naturally occurring PIP-binding 
domain (the PHD domain of nuclear ING2 protein) to successfully detect the elusive and 
poorly understood PI(5)P lipid.
2
 The affinity for PI(5)P demonstrated by the SEC14 
domain of Patellin1 therefore presents a particularly exciting opportunity for lipid probe 
design. By studying the residues that make PI(5)P, among other PIPs, so attractive to 
PATL1, the Elmore lab can begin to construct PIP detection proteins with appropriate 
binding affinities and functional GFP tags. While these designer proteins will still likely 
alter natural cellular function to a certain degree, it may be advantageous to incorporate 
them into a mammalian cell since they do not already have a designated role there and 
will therefore not be redundant. 
 In addition to their value as tools for studying the behavior and cellular 
concentrations of regulatory inositol lipids, these GFP-tagged membrane domains have 
some potential for use in clinical settings. As previously discussed, diseases involving 
malfunctions in PI-regulated pathways often result in an imbalance of membrane 
 14 
phosphoinositides, with one or more inositol lipids present in greater concentrations than 
usual. Numerous protein domains have been shown to interact specifically with 
PI(3,4,5)P, the phosphoinositide overproduced by aberrations in the PI3K/PTEN 
pathway. By recognizing that abnormal amounts of a particular phosphoinositide are 
present in a cell, one can evaluate the likelihood that the affected person has a disease 
associated with that phenotype, which can in turn guide the treatment of that disease. For 
instance, cancers caused by mutations in proteins and enzymes of the PI3K pathway have 
specific prognoses and are sometimes resistant to certain forms of treatment.
20
 If a patient 
with cancer is shown, through live-cell imaging, to have an excess of PI(3,4,5)P in his or 
her cells, medical professionals can determine that the cancer is the result of a breakdown 
in function of one of the main enzymes in the PI3K pathway. From there, they can focus 
genetic tests on genes encoding those enzymes and ultimately ascertain the proper 
treatment based on the molecular basis for the disease.  
 
Proposed Protein-Lipid Binding Assays  
 Although vesicle cosedimentation assays proved adequate for initial binding 
studies, we plan to find a less expensive and more quantitative method to detect small 
changes in binding affinity between different protein-lipid combinations. Ideally, such a 
method would allow us to determine the binding patterns of WT PATL1 and its mutants 
with enough precision to determine which of the aforementioned computational methods 
was most accurate. To this end, three methods were proposed. The first, fluorescence 
spectroscopy, takes advantage of the fact that aromatic residues are excited when exposed 
to ultraviolet light. Tryptophan and tyrosine are both excited near 280 nm in polar 
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environments, and this key characteristic is often useful for determining the protein’s 
surroundings and, therefore, its affinity for a given lipid. In a largely hydrophobic 
environment, once tryptophan and tyrosine are excited, the peaks in their emission 
spectra (between 300 and 450 nm) begin to show up at shorter wavelengths. This 
phenomenon is known as a blue shift. 
39
  
 The second proposed technique is isothermal titration calorimetry (ITC). This 
technique has been used widely for evaluating protein-lipid binding
40, 41, 42, 43
 and is 
highly quantitative, with the ability to provide the thermodynamic parameters ΔH, ΔS, 
and Ka for a given reaction. Two chambers, one of which contains sample in buffer (the 
sample cell) and one of which contains the buffer alone (the reference cell) are enclosed 
in an adiabatic chamber. In order to maintain a constant temperature, each cell receives 
an appropriate supply of power. A feedback signal between the cells ensures that the 
amount of power supplied to the cells changes according to the heat (or lack thereof) 
generated in a given cell. Ligand is injected into the sample cell at regular intervals and 
the heat generated or consumed by the resulting reaction determines how much power the 
machine will supply to each cell. If an exothermic reaction occurs in the sample cell, for 
instance, less power is provided to that cell. Time lapses between the injections allow the 
power to return to its initial level before rising or dropping again. Overtime, the isotherm 
(a plot featuring the consequent peaks) is generated, and the areas of these peaks are 
calculated, providing the user with the ΔH of the reaction. Single site protein-lipid 
binding isotherms are characterized by the sigmoidal curve generated by the peaks over 
time. The relative steepness of the curve can be used to find Ka, which can in turn be used 
to find ∆G via the van’t Hoff equation. Because temperature is kept constant, the program 
 16 
can then calculate T∆S. 44 Because this method yields a concrete value for Ka, it offers the 
researcher a better mode of direct comparison between various lipid-protein 
combinations, allowing for a more precise analysis of PATL1’s specificity. Further, the 
program’s ability to calculate binding contributions from enthalpy and entropy makes 
ITC one of the few experimental methods that can qualitatively confirm computational 
calculations of hydrophobic (entropic) and electrostatic (enthalpic) contributions to 
binding stability.  Another practical advantage of this method over the vesicle 
cosedimentation assay is the relatively small amounts of sample required.  
 Researchers have also begun to explore equilibrium dialysis as a technique for 
measuring protein-lipid binding. Like isothermal titration calorimetry, equilibrium 
dialysis provides thermodynamic data about a given reaction. Due to its ease of use and 
the low concentrations of sample that it requires, the rapid equilibrium dialysis device has 
been employed for initial testing. Inserts contain two chambers, which are separated by a 
semipermeable (8K MWCO) cellulose membrane. One chamber simply contains buffer, 
while the other contains protein and lipid samples. After an equilibration period (about 4 
hrs), solution is extracted from the buffer chamber, and the amount of lipid in the solution 
is quantified. The concentration of free ligand in the buffer chamber can be assumed to be 
equal to the concentration of free ligand in the sample chamber (because equilibrium is 
assumed).
45,46
 After the development and optimization of a binding assay is complete, it 






MATERIALS AND METHODS 
Protein Purification 
 Vectors and Protein Samples. Protein was produced via BL21(DE3)pLysS 
Escheria coli cells engineered with the plasmid pGEX6-PATL1(1-573).  Addition of 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) to the cells induced overexpression of 
glutathione S-transferase (GST)-PATL1. 
 Overexpression of the PATL1 pGEX-6P-1 Strain.  Two milliliters of Luria 
Broth (LB) media (10g/L tryptone, 5 g/L yeast nitrogen base, 10 g/L NaCl, 1 mM NaOH) 
with ampicillin (50 ug/uL) were inoculated with pGEX6-PATL1 BL21(DE3)pLyS E. coli 
cells from frozen stock. The cells were incubated overnight at 37°C on a rotor shaker and 
plated on LB Agar containing ampicillin. Twenty-five milliliters of LB media with 
ampicillin (50 ug/uL) were inoculated with genetically identical BL21(DE3)pLysS E. 
coli cells from one colony on the plate and grown at 37°C on a rotor shaker. Following an 
overnight incubation, the twenty-five milliliter culture was added to 500 mL of LB media 
and ampicillin. These cells were incubated at 37°C to late log phase (A600 = 0.8 – 1.0), 
or for between 1.5 to 2.5 hours. After cells reached a viable A600, PATL1 production 
was induced with 0.5 mL IPTG (0.5 mM), and cells were incubated at 37°C in the shaker 
for an additional four hours. Induced cells were pelleted at 6500xg for 10 minutes and 
washed once in about 200 mL of cold 1XPBS. Finally, cultures were resuspended in 11 
mL lysis buffer (1% Triton, 0.2 M NaCl, 2 mM EDTA, 20 mM NaPi at pH 7.5, 5 mM 
DTT, 2 mM AEBSF, 1 Roche mini protease inhibitor tablet) and frozen at -80°C. 
 GST-Affinity Purification. Lysed cell membranes were further ruptured through 
sonication with a probe (specify) on ice at an output level of 7 and a 75% duty cycle. The 
 18 
lysate was centrifuged at 20,000xg and 4°C for 30 minutes to separate the protein from 
cell debris. The supernatant (containing the protein) was combined with 1.5 mL of a 50% 
slurry of washed GST-Sepharose beads (GE Healthcare) in a round-bottom tube and 
placed on a roller for 2 hours at 4°C. The protein-bound beads were pelleted for 5 
minutes at 500xg and then washed 5-10 times with about 10 mL of cold PBS. Between 
washes, the beads were pelleted at 500xg for 1-3 minutes. After the last wash, beads were 
transferred to a microcentrifuge tube along with one mL of elution buffer (0.15 M NaCl, 
100 mM Tris at pH8, 20 mM GSH). The beads were then placed on the roller for 30 
minutes at 4°C and pelleted at 500xg for 10 seconds immediately following the 
incubation. One milliliter of protein solution was removed from the microcentrifuge tube, 
and 1-3 more elutions were performed.  
 Determining Protein Concentration and Purity. Protein quantities were 
determined from the A280 absorbance of tryptophan (and to a lesser extent, tyrosine) 
with a Thermo Scientific NanoDrop2000 spectrophotometer. (Extinction coefficient = 
92472 /M cm) Beer’s law was subsequently used to determine molar concentrations. SDS 
polyacrylamide gel electrophoresis was performed with samples of uninduced and 
induced cultures as well as with dialyzed elutions. The samples were loaded along with 
2X SDS sample buffer onto 7% Tris-HCl protein mini-gels (Bio-Rad Life Sciences) 
alongside a 10-170 kDa protein ladder (Thermo Scientific). Gels were run in a Tris and 
glycine buffer. Gels were rinsed three times in five-minute intervals and then fixed with 
Coomassie Blue Stain (brand name) for one hour, rinsed for an additional half hour, and 
photographed using a Verizon phone. 
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Rapid Equilibrium Dialysis 
 PATL1 was injected into a 7 kDa molecular weight cutoff slide-a-lyzer dialysis 
cassette (Thermo Scientific Pierce) and submerged in a beaker filled with about 300 mL 
of lipid binding buffer (10 mM MOPS, 0.15 M NaCl, 0.1 mM EDTA, pH =7.0) for every 
mL of PATL1 solution (typically 1 – 3 mL) to be dialyzed over two hours. The buffer 
was then replaced with fresh lipid binding buffer and, after another 2 hours, was 
refreshed once again. The slide-a-lyzer remained in the lipid binding buffer for an 
additional twelve hours, after which the PATL1 solution was removed from the dialysis 
cassette. The sample was concentrated by centrifugation in a Nanosep tube (VWR) with a 
30 kDa molecular weight cutoff. It was then brought up in 100 uL lipid binding buffer 
and transferred to the sample cell of a Rapid Equilibrium Dialysis (RED) insert (Thermo 
Scientific Pierce). An equivalent concentration of soluble phosphoinositide lipid (Echelon 
Biosciences) in lipid binding buffer was also added to the sample cell, so that the final 
sample volume was 100 uL. 300 uL of lipid binding buffer were transferred to the 
adjoining RED insert cell. Vacu-seal tape was placed over the RED inserts, which were 
kept in a 48-well teflon base plate. The samples were incubated at 37 °C on a rotator-









 A set of standards containing 0, 5, 10, 25, 50, and 100 uL of 0.65 M phosphate 
buffer were prepared in test tubes. 50 uL of solution from each sample cell and 100 uL of 
solution from each buffer cell were extracted from the RED inserts and transferred to test 
tubes. 450 uL of 8.9 N H2SO4 were added to the samples and standards, all of which were 
placed in an oven at 170-210 °C for 30 minutes. In order to neutralize the deep navy color 
characteristic to lipid samples that have been heated, 150 uL of H2O2 were added, and the 
samples were placed in the oven for an additional 25 minutes. If the solutions were still 
not completely colorless, additional 30 uL volumes of H2O2 were added to each solution, 
which were then heated in the oven once more for fifteen minutes. Once the solutions 
cooled, 2.9 mL of water, 0.5 mL of ascorbic acid, and 0.5 mL of aluminum (IV) 
molybdate were added to each test tube, followed by vigorous vortexing. The tubes were 
transferred to a boiling hot water bath for five to seven minutes, or until the solutions 
adopted a blue tint. Tubes were removed from the water bath and briefly allowed to cool. 
A820 absorbances were measured for each sample with a UV-Vis spectrophotometer. 
Concentrations of phosphate in the sample tubes were determined from a curve generated 
by the set of standards. The molar ratios of phosphate to lipid were used to quantitate the 
lipid concentration in each sample. 
Tryptophan Fluorescence  
 PATL1 was dialyzed against lipid binding buffer as described for rapid 
equilbrium dialysis. One four-sided 700 uL quartz cuvette with a pathlength of 10 mm 
(model 18F- Q-10, Starna Cells, Atascadero, CA) was prepared with a 2.5 × 10
-6
 M 
concentration of dialyzed PATL1 in lipid binding buffer. Another was prepared with a 
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0.001 M tryptophan solution. Each cuvette was placed in the Cary Eclipse fluorimeter. 
Their contents were excited at 280 nm, and the resulting emission spectra were recorded 
from 300 to 450 nm. Lipid (either 10:1 PE:PI large unilamellar vesicles, soluble PI, or 
soluble PI(5)P) was incrementallly titrated into each cuvette in quantities of about 1.75 × 
10
-9
 mol per injection, and given five minutes to equilibrate following their addition to 
the PATL1 and tryptophan solutions before each spectrum was recorded. After five to 
seven scans were taken, the cuvettes were removed, washed (there were only two of 
them), and replaced by a cuvette containing 2.5 × 10
-6
 M PATL1 solution, which served 
as the blank for the meaurements. The emission spectra of the PATL1 + lipid solutions 
were normalized with respect to the blank and the light scattering effects of the lipid 
(taken into account by cuvette containing tryptophan + lipid), before being plotted. 
Isothermal Titration Calorimetry 
 Initially, PATL1 samples were spun “dry” in 30 kDA molecular weight cutoff 
nanosep tubes (VWR) and reconstituted in HEPES buffer  (10 mM HEPES, 45 mM 
NaCl, 1 mM EDTA, pH = 7.4) or in lipid binding buffer. After it became clear that this 
practice was not removing all of the glutathione from the PATL1 sample, the more 
extensive dialysis process described above was put into place for ITC samples. These 
PATL1 samples were then concentrated by centrifugation using nanosep tubes with a 30 
kDa molecular weight cutoff and brought up in 2 mL of lipid binding buffer. 400 uL of 
lipid solution were prepared in lipid binding buffer at 10X the concentration of the 
protein solution. Lipid and PATL1 samples were degassed with a vacuum tube apparatus 
for five minutes. The lipid sample was pipetted into the culture tube, and a long syringe 
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was used to transfer the PATL1 solution into the sample cell. After the lipid solution was 
drawn into the injection syringe, the syringe was placed directly over the sample cell.  
For earlier studies, the ITC was programmed to inject 30 10-uL volumes of lipid 
into the protein solution, with three minutes between each injection at 25 °C. Later, this 
approach was altered in an attempt to produce a stronger signal. 24 12-uL volumes of 
lipid were titrated into protein solution, with four minutes between them and the 
temperature set to 20 °C. A control (equivalent volumes of lipid injected into lipid 
binding buffer) was also run in order to ensure that heats of binding, and not merely heats 
of solvation, were producing the observed peaks. Results were analyzed in the Microcal 
software suite. The buffer background was subtracted from the isotherm produced by the 
solution of interest and a plot was fit to the resulting points. Thermodynamic parameters 
were calculated based on that plot.  
 Circular Dichroism Spectroscopy 
 PATL1 samples were dialyzed in 1mM NaH2PO4 buffer as described above. 300 
uL samples of 0.12 uM concentrations of PATL1 in 1mM NaH2PO4 buffer were 
transferred to rectangular 400 uL quartz cuvettes with a pathlength of 1 mm.(model 21-
Q-1, Starna Cells,  Atascadero, CA). Three scans were taken for each spectrum with a 
constant integration time of 60.0 seconds. The temperature was set to 25 °C, and spectra 
were recorded from 195 – 250 nm. Unfolded samples contained quantities of urea 





RESULTS AND DISCUSSION 
The Interaction Between PATL1 and Phosphoinositides is Weakly Exothermic 
 In contrast to other methods for studying protein-ligand binding, isothermal 
titration calorimetry offers the distinct advantage of breaking an interaction down into its 
enthalpic and entropic components. It does this by calculating the fundamental 
thermodynamic parameters involved in a given reaction. The heat evolved when lipid is 
titrated into protein solution in the sample cell is measured against the static background 
provided by a thermally coupled reference cell, which contains only buffer or water.  
Electrical feedback between the cells allows the instrument to keep them at a common 
temperature (Figure 6). The differences in power supplied to each cell to maintain their 
common temperature (the differential power or DP) is monitored by the instrument and 
plotted as peaks. Peak areas are then integrated over the amount of time required for the 
sample cell to return to baseline power, and the results of these integrations are recorded 
as integral heats. The direction of the peak’s deviation from the baseline indicates 





















Figure 6.  Exothermic binding induces a decrease in power supplied to the sample 
cell. The heat produced by an exothermic protein-lipid binding interaction is 
counterbalanced by a decrease in power supplied to the sample cell, which is shown as a 
sharp peak. Instrument software integrates the peak to determine heat of binding with the 
following formula: . 
 
Because ITC experiments are conducted at a constant pressure and volume, the 
heat evolved by a reaction can be equated to the change in the system’s internal energy, 
which can in turn be equated to its change in enthalpy. The association constant, K, can 
be found from this relationship. The binding association constant is in turn used in the 
van’t Hoff equation to determine the change in Gibbs free energy, thus providing all of 
the values necessary to calculate the change in entropy for the system. Many studies 
investigating phosphoinositide detection proteins have employed the technique, not only 
to evaluate protein selectivity for particular lipids,
47
 but also to reveal information about 
their mechanisms of binding by determining binding stoichiometry (n values) 
48
 and 
comparative heats of binding prior to and after amino acid mutagenesis.
49
  
A preliminary ITC run with very low concentrations of lipid and protein showed a 
strong but erratic signal (Figure 7). Low concentrations were used because a major 












N 1.00  
K 5.48E4 + 3.34E6 






Figure 7. PI(5)P titrated into PATL1 generates a highly negative, irregular  
isotherm. (A) Thirty 10-uL injections of 0.001 mM PI(5)P in HEPES (pH = 7.4) were 
titrated into 0.0001 mM PATL1 in HEPES. Cells were maintained at a constant 
temperature of 25°C. (B) After baseline adjustments were made and a buffer background 
was subtracted, the experimental isotherm could not effectively be fit by a line. (C) The 
lack of a true line fit produced thermodynamic values with standard deviations greater 
than the values themselves.  
 
The relatively large heats of binding produced, coupled with the characteristic tapering of 
the peak heights over time (beginning around 90 minutes into the experiment) seemed to 
indicate that ITC could be a viable method for measuring binding strength. Prior to its use 
for calculating thermodynamic values in Origin, the raw data were altered slightly. The 
baseline from which the peaks are integrated was shifted with respect to several peaks to 
better reflect actual changes in differential power, and a buffer background (equivalent 
injections of PI(5)P into HEPES) was subtracted from the plot in order to eliminate 
contributions from heats of solvation. The subsequent isotherm did not follow a distinct 
trend (B) and the thermodynamic values were extremely imprecise (C), but because the 
A B 
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magnitudes of the peaks were so large, it was deemed worthwhile to repeat the 
experiment with greater concentrations of protein and lipid. In order to minimize protein 
loss, there was no attempt to cleave the GST-tag off of PATL1 prior to the following 
experiments. 
 Despite the fact that the protein and lipid concentrations were increased about 50-
fold, the signal generated by the next ITC run was much lower than that of the previous 
















Figure 8. PI titrated into PATL1 generates a weakly exothermic binding interaction. 
(A) Thirty-six 8-uL injections of 0.05 mM PI in HEPES (pH = 7.4) were titrated into 
0.005 mM PATL1 in HEPES. Cells were maintained at a constant temperature of 25°C. 
(B) After a buffer background was subtracted, the experimental isotherm exhibited a 
weak, but more defined line. (C) Much lower, slightly more precise thermodynamic 
values were generated from this line fit. 
 
However, the titration curve was more easily fit to a line, and the calculated 
thermodynamic parameters, though still imprecise, showed much smaller standard 
Thermodynamic Values 
N 1.00  
K 2.55E4 + 8.62E3 





deviations. Because such low heats of binding were observed, another equation was 
employed to determine whether or not accurate thermodynamic values could be 
determined for binding interactions between PATL1 and phosphoinositol lipids. Using 
the Langmuir equation and binding data from original PATL1-vesicle cosedimentation 
assays (Figure 4), approximate K values were calculated. The equation to find c is as 
follows,  
                                                           c = KMtotn    (Equation 1) 
where Mtot is the concentration of protein in the sample cell in the beginning of the 
experiment and n is the number of binding sites. The calculated K values (Table 1) 
definitively showed that even for the PI lipids that bound strongest to PATL1, the 
concentrations of protein and lipid were far too low for the ITC to generate meaningful 
thermodynamic parameters. The ideal range for these c values is between 5 and 500.  
Lipid Ka c 
PI(5)P 437 2.18E-03 
PI(4,5)P 303 1.52E-03 
PI(3)P 152 7.58E-04 
PI(3,5)P 80 4.01E-04 
PI 11 2.47E-05 
Table 1. Approximate association constants and c values of different PI lipids. 
Despite the fact that, according to equation 1, PATL-PI interactions would not be 
strong enough to generate reliable thermodynamic parameters, there was still some 
question of whether or not the method could evaluate the binding strength of PATL1 to 
different phosphoinositol lipids on a more qualitative level. Several measures were 
therefore taken to amplify the observed signal so that comparisons could be drawn more 
easily. To this end, three variables were changed. The first was increasing injectant 
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volumes (to 12 uL) in order to saturate the protein early on in the titration and thereby 
create more defined peaks in the beginning of the experiment. Additionally, the 
experimental temperature was lowered by five degrees in order to shift the equilibrium of 
the binding reaction toward the products, since it was previously shown (Figure 8) to be 
exothermic. Finally, the macromolecule solutions were prepared in “lipid binding” 
MOPS buffer (pH = 7.0) as described by Peterman, et al. (2004) in the event that PATL1 
would be more active at this lower pH. However, notable differences were not observed 
between PI and PI(5)P, despite the fact that PI(5)P’s association constant is about 40X 

















































K 2.55E4 + 8.62E3 




K 2.55E4 + 8.62E3 
ΔH -9.988E4 + 2.588E4 
ΔS -315 
 
Figure 9. PI and PI(5)P titrations did not generate significantly different isotherms. 
(A) Twenty-four 12 uL injections of 0.05 mM PI (left) and PI(5)P in 10 mM MOPS 
buffer (pH = 7.0) were titrated into 0.005 mM PATL1 in MOPS buffer. Cell temperatures 
were maintained at 20°C (B) These titrations produced weakly exothermic isotherms that 
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were not notably different form one another. (C) Imprecise thermodynamic values were 
produced by the line fits. 
  
Clearly, ITC is not a suitable method for determining either the quantitative or qualitative 
binidng selectivity of PATL1. The large enthalpic values generated by the first ITC 
experiment (Figure 7) were most likely due to the presence of air in the injection syringe 
(a lower than recommended volume of lipid was used) and artifacts from the purification 
and GST-cleavage processes. 
 
Equilibrium Dialysis Indicates Potential for Bacterial Phospholipid Co-purification 
 The inability of ITC and tryptophan fluorescence to yield quantitative data about 














Figure 10. The 48-well teflon Rapid Equilibirium (RED) plate can hold up to 48 
pairs of sample and buffer chambers, or inserts. The binding constant of the protein 
being analyzed can be determined by the free lipid concentration in the buffer chamber. 
 
A simple but elegant method, rapid equilbirium dialysis (RED) depends on a membrane 
with a low molecular weight cutoff to confine large proteins and protein-ligand 
complexes to one side of the dialysis insert. Smaller free ligands are then free to move 
between the cells of the dialysis inset. By measuring the free ligand concentration of the 
buffer cell, one can reasonably infer that the measurement is equal to the free ligand 
concentration of the adjacent sample cell since the system is in equilibrium. Once the free 
ligand concentration has been determined, the binding constant for the reaction is 
calculated by the Hill equation. The straightforward nature of this technique was 
appealing given that the instrumental techniques that had been attempted were not 
adequately sensitive.  
Preliminary dialyses in which only lipid was added to the sample chamber were 
perfomed, and they showed that low concentrations of lipid (5.0 to 25.0 uM) could be 
detected within an order of magnitude by the colorimetric phosphate assay. The assay 
consistently measured only 39% of the lipid added within a relative error of 5%. 
Although this ruled out any possibility of accurately calculating a K value at such low 
concentrations, the relative consistency in the error (thought to be caused in part by lipid 
binding to the walls of the RED insert) indicated that the method would be suited to 
evaluating relative binding quickly and cheaply. The teflon “plate” in which the RED 
inserts are held during the equilibration period can hold up to 48 inserts at any given 
time, which would allow for quick screens of multiple phosphoinositide and PATL1 
mutant combinations. Any combinations showing particularly strong binding could then 
 32 
be studied further at higher concentrations, ideally producing a more quantitative binding 
profile. 
For the first RED experiment, equal concentrations of PATL1 and PI(5)P were 
transferred to the “experimental” insert, which was equilibrated in the teflon plate along 
with two control inserts which contained PI(5)P alone at the same concentration found in 
the experimental insert. Final concentrations of phosphate were determined in both the 
sample and buffer chambers of all three inserts. Surprisingly, the phosphate concentration 
in the buffer chamber of the experimental insert was found to be substantially greater 
than that of the buffer chamber of the controls, suggesting that its “free” lipid 
concentration was much higher. Ordinarily, this result would suggest that the percentage 
of  lipid “bound” to protein was greater in the control inserts (which, again, contained no 










Figure 11. Experimental RED insert contained twenty-three times more phosphate 
than the control inserts. PATL1 and an equal concentration of PI(5)P lipid were added 
to the sample chamber of the experimental RED insert. An equivalent amount of PI(5)P 
was added to control inserts. All samples equilbrated for four hours at 37 °C before 
undergoing the phosphate assay.  
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However, this was clearly not the case. A comparative evaluation of phosphate 
concentrations in the sample chambers shed considerable light on the matter. Absorbance 
values indicated that more phosphate was present in the experimental RED insert than 
could have originated from the addition of phospholipid alone. Notably, there was about 
2.6 times more phosphate in the experimental sample chamber than in the corresponding 
buffer chamber. Excess PBS buffer from the PATL1 purification process seemed a likely 
culprit for the high phosphate readings. 
 In light of this observation, the phosphate concentrations of two disperately 
prepared protein samples (each without lipid) were compared. One sample had been 
concentrated via centrifugation in a nanosep tube and reconstituted in MOPS buffer, and 
the other was exhaustively dialyzed against MOPS buffer for sixteen hours. Absorbance 
values showed that the first sample contained over twenty-three times the amount of 










Figure 12. Dialyzing PATL1 effectively reduces the amount of phosphate in PATL1 
samples. PATL1 samples were subjected to buffer exchange (eluation to MOPS buffer) 
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via Nanosep tube centrifugation in one case and exhaustively dialyzed against MOPS 
buffer in the other. The dialyzed protein sample shows very little phosphate in its sample 
chamber, and no phosphate in its buffer chamber, suggesting that all of the remaining 
phosphate is bound to the protein. 
 
The phosphate concentration determined for the dialyzed sample chamber was on the 
same order of magnitude as the protein concentration in the sample, and tellingly, only 
the sample chamber showed evidence of phosphate impurities. It was therefore clear that 
the phsophate was binding to the protein in some way. The fact that the phosphate and 
PATL1 appeared in a nearly 1:1 molar ratio suggested that the phosphate contamination 
could potentially be attributed to the co-purification of phospholipid with protein in the 
BL21 E. coli  cells.  
Although phosphoinositides are not part of the membrane composition of natural 
E. coli  bacteria, the abundance of phospholipids such as phosphatidylcholine and 
phosphatidylethanolamine, make it reasonably likely that such an event would occur. 
Further, previous studies showing PATL1’s extractability from bound phospholipid with 
urea and NaCl indicate that its binding is dependent on both hydrophobic and 
electrostatic effects, respectively. 
35
 It follows that, although the favorable electrostatic 
component of  binding would be missing if PATL1 were to bind a lipid without a 
negatively charged inositol headgroup, its largely hydrophobic binding pocket would still 
be amenable to occupation by phospholipid with similarly-sized hydrophobic tails, 
regardless of headgroup charge or lack thereof (Figure 13).  Additionally, some bacerial 
phospholipids, such as phosphatidylserine, are anionic as well. 
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Figure 13. Phosphatidylinositol (left) and Phosphatidylcholine (right) bind the Sec14 
lipid binding domain of PATL1. Crystal structures of PI and PE in the hydrophobic 
pocket of PATL1’s Sec14 binding domain show that their occupation of the binding site 
is qualitatively similar. Namely, their hydrocarbon tails are positioned almost identically 
and interact with many of the same residues. 
 
Further, any “competitition” between the previously bound phospholipid and added 
phosphoinositide would be discouraged by the solvation penalty inherent in releasing the 
co-purified lipid into solvent in order to bind the newcomer. 
 Protein denaturation was attempted in order to expel any latent phospholipid that 
may have co-purified with the protein. A labmate’s difficulties with thermal denaturation 
and the strange circular dichroisom spectroscopy measurements it produced (Mwangala 
Akamandisa, personal communication), made chemical denaturation the more viable 
option. Urea was chosen for this purpose, since it is a standard denaturant and less 
destructive than the other commonly cited chemical option, guanidium hydrochloride. 
Urea was added to PATL1 in elution buffer, and the solution was dialyzed against MOPS 
buffer (pH = 7) for sixteen hours in a “slide-a-lzyer” dialysis cassette. The cassette, 
unlike the RED insert, is designed for thorough buffer exchange, rather than for 
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experiments in protein-ligand binding. The hope was that simultaneously dialyzing the 
elution buffer and the urea would allow the protein to unfold, disassociate from the lipid 
once its secondary and tertiary structures could no longer suppport binding, and refold in 
the correct buffer. The resulting solution would therefore be rid of co-purified 
phospholipid and any residual phosphate from the elution buffer. The A820 values for 
this solution were compared to those of PATL1 in elution buffer (for which no alterations 
were made subsequent to the purification) and those of PATL1 extensively dialyzed in 
MOPS without Urea. A280 values (the absorbance of the protein residues tryptophan and 
tyrosine at 280 nm, used to quantitate protein) for each sample were measured 
immediately prior to the phosphate assay, so that the molar ratios of PATL1 and 
inorganic phosphate could be calculated and compared (Figure 14). 
 
Figure 14. Comparative Phosphate:PATL1 ratios in disparately prepared protein 
samples. Protein was purified as described on page 18. Without any further treatment, 
purified protein samples showed much greater A820 values than those that had been 
dialyzed against MOPS for sixteen hours and those that had been treated with 2.3 M urea 
and dialyzed against MOPS for sixteen hours. 
 
Exhaustive dialysis against MOPS buffer reduced the protein sample phosphate 
concentration by over seven-fold. More notably, the difference in phosphate 
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concentration between the sample treated with urea and the sample that had not been 
treated with urea was signficant to the 95% confidence level. While this difference cannot 
definitively be accounted for by the expulsion of lipid from the denatured protein’s 
binding site, it is confirmation that the addition of urea alters the sample in such a way as 
to lower its A820 value. With that said, the absorbance values for each sample were still 
surprisingly high even after the addition of the sixteen-hour purification step.  One may 
notice that the high ratio of phosphate to PATL1 was somewhat inconsistent with 
previous data (Figure 11), which showed that they were present in either very similar 
concentrations or that the moles of PATL1 outnumbered those of phosphate. Because the 
protein concentration was not measured immediately prior to the phosphate assays during 
the earlier experiments, however, (concentrations were measured after they were dialyzed 
but not after they were spun down, a step that often results in loss of PATL1) it is likely 
that the final amount of protein in each sample was overestimated, creating a more even 
distribution than actually exists. 
 
Addition of Urea Induces Random Coil Formation in PATL1 
 Because so much phosphate remained in the PATL1 samples, it was impossible to 
say with certainty whether the protein’s binding site was being occupied by a 
phospholipid and whether or not that lipid was released subseqent to dialysis with urea. 
However, studies using circular dichroism spectroscopy, which uses circularly polarized 
light to elucidate protein secondary structure, showed that PATL1 unfolded with the 
addition of urea (Figure 15). Therefore, a mechanism in which the lipid dissociates from 
PATL1 once the protein is in its unfolded state is entirely conceivable. The peak of the 
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the spectrum in Figure 1(B), which occurs near 220 nm following an abrupt rise, is strong 
evidence that the percentage of random coil in the protein has increased.  
A decrease in alpha-helical character also seems to be in evidence. This decrease would 
undboutedly affect the binding site of PATL1, whose “walls” are lined by four crucial 
alpha helices and whose hydrophobic binding pocket is thought to be “gated” by an 















Figure 15. (A) CD spectra of PATL1 alone and (B) with the addition of 2.3 M urea, 
in 1 mM NaH2PO4  buffer. 
 
This shift toward a more disordered structure indicates that the addition of 2.3 M 
urea does induce the denaturation of PATL1 to a certain extent. Additionally, a saturated 
solution of urea (18.18 M) was added to a sample of PATL1 (for a final concentration of 
6.6 M) to be exhaustively dialyzed against 1 mM NaH2PO4 , this time for a total of 
twenty hours. The spectrum for PATL1 exposed to 6.6 M urea was the most disordered, 












Figure 16. CD Spectra of PATL1 in 1 mM NaH2PO4  buffer with the addition of  
6.6 M Urea. 
 
With PATL1’s denaturation in the presence of 2.3 and 6.6 M urea confirmed, it 
became pivotal to determine if the protein was refolding following dialysis. Determining 
whether PATL1 can refold on its own after denaturation stress is interesting in its own 
right and also extremely relevant when thinking about its binding here. A crucial criterion 
for the success of an added purification step involving dialysis is its ability to maintain 
the integrity of the protein.  A CD spectrum taken of PATL1 after to its exposure to 6.6 
M urea and dialysis that followed showed that, unfortunately, this was not the case 
(Figure 17). While the structure was not quite as disordered as the samples that had been 
directly exposed to 2.3 and 6.6 M urea while analyzed, its spectrum also exhibits the rise 
near 220 nm and subsequent flattening that is characteristic of random coil structures 
(Figure 16). Although the integrity of the protein was compromised by the denaturation 
step in this particular case, it is somewhat encouraging that the spectrum of PATL1 post-
urea exposure and dialysis has greater alpha-helical character than the protein sample 
directly exposed to 6.6 M urea. This suggests an ability to refold, even if the process did 
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not go to completion. The data below paired with tryptophan fluorescence data (Section 
whatever) indicate that some urea probably remains in the sample. This suggests a need 




Figure 17. CD spectrum of PATL1 after addition of 6.6 M urea and subsequent 




Tryptophan Fluoresence is Currently Not Viable for PATL1-Lipid Binding Studies 
 Tryptophan fluorescence spectroscopy operates under the principle that 
tryptophan and, to a lesser extent, tyrosine, are both excited to higher energy states by 
exposure to light at 280 nm. They then emit light of wavelengths between 300 and 450 
nm. In hydrophobic environments, they tend to emit light on the lower end of this 
wavelength range, creating a “blue shift.” This technique has been used with great 
frequency in the Elmore lab, primarily to study interactions between small peptides and 
lipid vesicles. Greater interaction between the macromolecules is indicated by the gradual 
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development of a blue shift, whose magnitude is proportional to the strength of the 
interaction. Due to its past success in the lab, it was the first technique tried when the 
Elmore lab began its investigation of PATL1’s binding properties. Two trials were 
initially conducted, one of which used 10:1 PE:PI vesicles, and one of which used soluble 
PI lipid. Neither form of the lipid managed to induce a blue shift when titrated into 
PATL1 solution. In fact, a slight “red shift” to the right was actually observed instead 
(Figure 18). 
 
Figure 18. Titrating 10:1 PE:PI lipid vesicles into PATL1 solution did not produce a 
blue shift. The PATL1 did not appear to interact with the PI lipid at any point during the 
titration. After the maximum amount of lipid (28.98 uL) had been added, the spectrum 
appeared to be somewhat red-shifted.  
 
The failure of the technique was attributed to the fact that out of seven tryptophan 
residues residues in PATL1’s amino acid sequence, only one is in the binding site. The 
small peptides the Elmore lab had traditonally used in these experiments contained only 
one Trp residue, which was integrally involved in the protein-lipid interactions being 
studied. Because the majority of Trp and Tyr residues in the PATL-GST complex are not 
involved in phospholipid interactions, it was decided that the lack of signal produced by 
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these inactive residues would have obscured any evidence of interactions between 
PATL1 and PI. 
 However, when we began to speculate as to the presence of co-purified 
pospholipid in the PATL1 bindng site, a new explanation for the lack of a blue shift in the 
early trials presented itself. Should competition have existed between the latent 
phospholipid and the phosphoinositides added to the PATL1 solutions, the fluorescence 
spectra would not have shown any difference between the bacterial phospholipid- and PI-
bound states. Because it only registers change in terms of the polarity or hydrophobicity 
of a molecules’s environment and does not discriminate between the causes of those 
changes, a 1:1 lipid exchange in the binding site would not indicate PATL1’s ability to 
bind specific lipid. Once the effort to expel potential co-purified lipid molecules from the 
binding site began, curiosity as to how this might change tryptophan fluorescence spectra 
arose. The PATL1 that had been treated with 6.6 M urea and then dialyzed in MOPS 
buffer was evaluated and the resulting fluorescence data were compared to those 
collected over the summer (Figure 18). Interestingly, when these data were normalized 
and overlaid, it became clear that the emission spectrum produced by the untreated 
preliminary protein sample was blue-shifted (and therefore in a relativey hydrophobic 
environment in comparison to the sample that had been denatured and dialyzed (Figure 
19).  This finding further supported the idea that co-purification was occuring and also 
validated the approach we had taken to expel the lipid. The fact that denatured and 
dialyzed sample appeared to be in a less hydrophobic environment would suggest that 
lipid had, in fact, been in the binding site and that it had been able to exit once the protein 




Figure 19. PATL1 solution that was denatured and subsequently dialyzed 
was blue-shifted in comparison to untreated PATL1 solution. Two PATL1 
samples, one of which had been denatured with 6.6 M urea and subsequently 
dialyzed against lipid binding MOPS buffer (pH = 7.0) for 16 hours, and one of 
which had only received the standard purification treatment described on page 
18, were excited at 280 nm. Their emission spectra were measured prior to the 
addition of any lipid and fit to a polynominal in Origin. The spectrum of the 
denatured and dialyzed sample showed a peak at 338.0 nm, while the untreated 
sample’s spectrum showed a peak at 336.4 nm. 
 
In addtion to measuring the emission spectrum of the denatured and dialyzed 
PATL1 sample prior to the addition of lipid, we conducted a titration with PI(5)P and 
measured the emssion spectrum after each lipid addition. Although a very faint blue shift 
could be detected once the maximum amount of lipid had been added (Figure 20), the 
evidence for binding was not quite as compelling as the evidence for co-purification 
shown in Figure 19.  
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  Figure 20. Titrating PI(5)P into denatured and dialyzed PATL1 did not  
produce a significant blue shift. PI(5)P was gradually titrated into PATL1 that 
had been treated to expel any co-purified lipid. Emission spectra were recorded 
after each addition and fit to a polynomial. Prior to the addition of any lipid, the 
spectrum peaked at 338.0 nm. Afer the maxiumum volume of lipid had been 
added (57 uL), a barely perceptible shift could be seen; the spectrum peaked at 
337.7 nm.  
 
Several factors could explain the fact that a blue shift was not observed in this 
experiment. As proposed earlier, the lack of response to the lipid from the fluorescent 
residues outside of the binding site may be weakening any signal produced by a potential 
shift in the emission spectrum of the tryptophan residue in the binding site.  
Another interesting prospect is that the structure of PATL1 may not have refolded 
into its proper binding conformation after being denatured with urea. As seen in Figure 
17, PATL1 treated with 6.6 M urea exhibited much more random coil than was observed 
in the native state, even after being dialyzed. Whether or not it was unable to refold 
because of problems during the denaturation and dialysis steps or because the was excess 
urea in solution afterwards is not entirely clear. However, the relatively low intensity of 
the emission spectra produced by the denatured and dialyzed protein (prior to 




Preventing Co-purification in the Lipid Binding Site 
 Several indications of bacterial membrane phospholipid co-purification have been 
illuminated over the course of this study. However, the techniques that were attempted to 
confirm their presence in the binding pocket have not been completely successful. The 
colorimetric phosphate assay is limited by its inability to distinguish between phosphate 
from lipid sources versus a “phosphate background” that appeared in all of the protein 
samples. In order for tryptophan fluorescence to elucidate whether or not phospholipid is 
being expelled from the binding site, the urea-treated protein and titrated 
phosphoinositide would need to interact strongly enough to produce a clear blue shift, 
which, as stated above, has been difficult to achieve for a variety of reasons. Should the 
denaturation step be developed well enough to adequately unfold the protein so as to 
release any interlopers in the binding site without leaving traces of urea in the sample, 
tryptophan fluorescence may prove to be a useful technique for determining whether or 
not co-purification is occuring. 
 However, a more straightforward method would be to compare the masses of 
some PATL1 samples that have been subjected to the denaturation step of the purification 
to those that have not using MADLI-TOF, a technique that ionizes macromolecules and 
sends them flying towards a detector, so that they are separated by mass and charge. If 
samples treated with urea are consistently less massive than their untreated counterparts 
by a specific value, it may indicate that co-purification has occurred and that the 
offending phospholipid has been removed. This does, of course, assume that any bound 
lipid will fly with the PATL1, which may or may not occur in practice.   
 46 
Despite the fact that (as will be discussed in the next section), PATL1 will 
probably not be used for future binding experiments, optimizing the lipid expulsion 
process will probably be an important aspect of any protein purification in live cells 
going forward. Varying the quantity of urea (or, potentially, another denaturant) and the 
amount of time that the protein is exposed to it will be good first steps towards this end. 
Another potentially useful approach would be to “double-dialyze” the protein by putting 
the protein solution into dialysis tubing that would then be placed in another dialysis 
tube, that would rest in the desired buffer solution. In this way, dialysis would be slowed 
down, and the protein would ideally unfold in such a way that it would be able to attain 
its previous conformation.  
 
Target Protein Selection 
 As binding studies go, Patellin1 is an attractive target protein for several reasons. 
Physiologically, its highly specific, yet unpredictable binding profile and special affinity 
for PI(5)P make it uniquely suited for study as a potential phosphoinositide detection 
protein. Additionally, and perhaps even more compelling, there is a wealth of 
computational data detailing its binding behaviors and the driving forces behind them. 
Not only are these data eminently valuable for understanding the binding mechanisms of 
patellin1 and predicting the most advantageous amino acid residues for its lipid binding, 
but they also have value as bases for comparing the accuracy of different computational 
methods. Interestingly, the three computational methods used predicted different 
qualitative results in terms of which residues were most important for binding different 
phospholipids. Experimental verification of these data would therefore be of great interest 
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both to biochemists and to computational chemists. However,  PATL1 has proven to be 
exceedingly difficult to work with in the laboratory. In this project as well as in past 
student work, research with PATL1 has been characterized by low purification yields and 
unsuccessful attempts to measure lipid binding.  
 While it would eliminate the opportunity to completely verify computational data 
regarding PATL1’s binding specificity, selecting a new target protein with the Sec14 
lipid binding domain could still answer many important questions prompted by 
computational analyses of PATL1-phosphoinositide binding, including which amino 
acids are most important for binding specific phosphoinositides. In fact, using an easily 
purified Sec14 domain as a scaffold for computationally informed design of highly 
specific phosphoinositide binding proteins seems significantly more effective and 
efficient than attempting to experimentally verify the binding behaviors of individual 
proteins. Although this study was not successful in its aims of experimentally verifying 
the binding of PATL1 with different phosphoinositides, it did highlight and attempt to 
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